Effect of Supplemental Oxygen Therapy on Neurocognitive Performance in Healthy Highlanders (SPIRIT_1)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Michael Furian, Prof. Dr.
- Phone Number: +41794037586
- Email: michael.furian@usz.ch
Study Contact Backup
- Name: Edith M Schneider, Dr.
- Email: edith.schneidergasser@usz.ch
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed written consent
- Age >18
- Kyrgyz ethnicity
- Born, raised and living at approximately 2500 m
- Native or fluent in Russian language
Exclusion Criteria:
- Severe disease such as unstable hypertension, coronary heart disease, pulmonary diseases, others.
- Regular use of medication that interfere with sleep or breathing such as benzodiazepines, opioids, acetazolamide
- Heavy smoking of >20 cigarettes per day
- Not able to read or adhere to the study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: SOT followed by Sham intervention
5L /min supplemental oxygen therapy through a nasal canula will be administered to the participants.
The intervention will start 5 minutes before the neurocognitive assessments and will be administered throughout the assessment.
After >4 hours of washout, the participants will repeat the neurocognitive assessments with 5 L/min sham intervention (room air).
|
5 L/min supplemental oxygen therapy administered through nasal canula.
5 L/min sham intervention administered through nasal canula.
|
|
Sham Comparator: Sham intervention followed by SOT
5L /min sham intervention (room air) through a nasal canula will be administered to the participants.
The intervention will start 5 minutes before the neurocognitive assessments and will be administered throughout the assessment.
After >4 hours of washout, the participants will repeat the neurocognitive assessments with 5 L/min supplemental oxygen therapy.
|
5 L/min supplemental oxygen therapy administered through nasal canula.
5 L/min sham intervention administered through nasal canula.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Psychomotor vigilance reaction time
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the reaction time during a 10-minute psychomotor vigilance test between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Trail making test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the trial making test A performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
|
Stroop test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the stroop test performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
|
Digit Span test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the digit span test performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
|
Go / No-Go test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the Go / No-Go test performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
|
N-back test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the n-back test performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
|
Task Switching Cued test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the task switching cued test performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
|
Flanker test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the Flanker test performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
|
Corsi Span test performance
Time Frame: Comparison between SOT and sham after 15 minutes intervention
|
The difference in the Corsi span test performance between SOT and Sham intervention.
|
Comparison between SOT and sham after 15 minutes intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Michael Furian, University of Zurich
- Principal Investigator: Edith M Schneider, Dr., University of Zurich
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SPIRIT_1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.